Literature DB >> 6269240

Pharmacokinetics of a new water-soluble nitrosourea derivative (ACNU) in human gliomas.

K Harada, K Kiya, T Uosumi.   

Abstract

The pharmacokinetics of a newly developed water-soluble nitrosourea derivative (ACNU) following a single intravenous injection was investigated in 11 patients with gliomas. A major portion of ACNU was excreted within 2 hours. The distribution rate was very fast, and the elimination rate tended to be slow. More than 50% of ACNU moves into the tissue compartment. ACNU tended to move into glioma tissue well. The ACNU level in glioma tissue was above 1.0 microgram/gm 30 to 60 minutes ater injections. ACNU was detected at a higher concentration in malignant gliomas than in benign gliomas. These results suggest that ACNU is taken up by tumor tissue relatively rapidly and eliminated slowly, which leads to effective manifestation of its antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6269240     DOI: 10.1016/s0090-3019(81)80022-5

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  8 in total

1.  Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

Authors:  K Anders; G G Grabenbauer; U Schuchardt; R Fahlbusch; R Fietkau; R Sauer; P Krauseneck
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Combined chemo- and radiosensitivity testing with ifosfamide and ACNU in human lung cancer cell lines.

Authors:  M Wolf; M Maasberg; R Pfab; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma.

Authors:  T Yamashima; T Ohnishi; Y Nakajima; T Terasaki; M Tanaka; J Yamashita; T Sasaki; A Tsuji
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

5.  Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy.

Authors:  F Vega; L Davila; G Chatellier; J Chiras; F Fauchon; P Cornu; L Capelle; M Poisson; J Y Delattre
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

6.  Delivery of a novel nitrosourea, MCNU, to the brain tissue in glioma-bearing rats. Intracarotid versus intravenous infusion.

Authors:  A Hodozuka; K Sako; H Nakai; M Tomabechi; N Suzuki; Y Yonemasu
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

7.  Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  In Sil Choi; Se Hoon Lee; Tae-You Kim; Jae Seug Bang; Sun Ha Paek; Suzy Kim; Il Han Kim; Dae Seog Heo; Yung-Jue Bang; Dong Gyu Kim; Hee-Won Jung; Noe Kyeong Kim
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

8.  Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.

Authors:  Tomokazu Aoki; Yoshiki Arakawa; Tetsuya Ueba; Masashi Oda; Namiko Nishida; Yukinori Akiyama; Tetsuya Tsukahara; Koichi Iwasaki; Nobuhiro Mikuni; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-10-11       Impact factor: 1.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.